Status:
WITHDRAWN
Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia
Lead Sponsor:
Johns Hopkins University
Conditions:
Primary Progressive Aphasia
Eligibility:
All Genders
50-90 years
Phase:
NA
Brief Summary
Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. There are three different variants of PPA, each a relatively distinct speech and la...
Detailed Description
A. Evaluation Tasks Language Tasks: Participants will be administered baseline language and cognitive tasks, including 1 or more of the following, depending on participants' residual language and co...
Eligibility Criteria
Inclusion
- Must be clinically diagnosed with nfvPPA or unclassifiable PPA. Diagnosis will be based on neuropsychological testing, language testing (most commonly the Western Aphasia Battery), MRI and clinical assessment.
- Must be right-handed.
- Must be speaker of English.
- Must have at least 9th grade education.
Exclusion
- Uncorrected visual or hearing impairment by self report.
- Stroke/other premorbid neurological disorder affecting the brain.
- Any other language-based learning disorder other than PPA.
- Inability to follow directions for baseline tasks.
- Western Aphasia Battery Aphasia Quotient (AQ) \<30 (indicating severe language impairment).
- Exclusion Criteria for MRI Participation:
- Severe claustrophobia.
- Cardiac pacemakers or ferromagnetic implants.
- Pregnant women.
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04486586
Start Date
April 1 2013
End Date
April 1 2025
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287